Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
about
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentagesErlotinib for advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerRecent progress in pancreatic cancerEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaPancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancerCurcumin AntiCancer Studies in Pancreatic CancerCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentPrognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysisSystemic Chemotherapy in Advanced Pancreatic CancerLocal Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A ReviewCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansManagement of pancreatic cancer in the elderlyAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsNeoadjuvant therapy for localized pancreatic cancer: guiding principlesManagement of borderline and locally advanced pancreatic cancer: where do we stand?Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateInterplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesisSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPancreatic cancer treatment and research: an international expert panel discussion.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic CancerImmunotherapy for patients with advanced pancreatic carcinoma: A promising treatmentGenetic factors affecting patient responses to pancreatic cancer treatmentMetastatic pancreatic cancer: Is there a light at the end of the tunnel?The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear StructureAdvances in chemotherapy for pancreatic cancerGemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysisPredictive modeling of in vivo response to gemcitabine in pancreatic cancerClinical Translation of Nanomedicine.Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
P2860
Q21092323-74A79A50-6B3A-486A-80F1-BD18516A9373Q24186983-9D6D73FC-ED97-40DF-9DA2-C4417D67ECA1Q24240739-8A853140-E054-4B1C-9370-D3E2178A23D4Q24245085-FCA5AFA7-A318-4AA5-8547-F78042AE30C2Q24626346-DF980298-E378-4DF7-9C2C-203A78D5E43CQ24627664-8BF49405-9737-4AB0-B982-DADB4232FF9DQ24631880-F9B57C49-0D6B-4B69-9C6B-DB1C408123BFQ26738714-41C9A289-E2AF-4A11-B497-9B584A71680AQ26740619-95D097D0-679F-44C9-9685-37BEFDB76753Q26747108-DB2212D5-6CA0-450D-B60E-BC22EA6FBC62Q26750440-7B86AD45-5161-4748-9457-3C0EF53596FBQ26765288-85E37AA3-317C-43E3-BEC6-A5002DD019D9Q26767041-C3516836-1BE6-41BB-A9FA-4F1E7028D1B9Q26774639-609CCBC3-6DD3-4516-A048-50A6F6023647Q26798674-A63A9CD3-85FB-473F-AFF7-95C268C3C438Q26799428-E604514A-5E43-4FBA-ABF8-9EF62C6B2F4AQ26825414-3D8C52D3-54EE-4B85-8B28-AFB2329763DBQ26828959-A168E1CB-EDA1-43CA-A983-EBD2E0436D43Q26830913-470DFE1B-7102-40E9-BB32-F6EABC3E102CQ26996794-C9E83EE7-7DA9-497D-8E66-E190B9DC6E19Q27021716-151D8585-E30D-4272-A47E-2955BF90FCAFQ27690868-FD157C24-AE4A-4C45-95E8-D88AD4CF70CDQ28066268-6BAD91BC-6D2A-48C9-93BF-92D466872026Q28066454-64248448-F2FA-4E70-A90B-7C3E323BC811Q28072210-9CE16BF2-96C3-4B90-BF6C-64AC40B55E22Q28074428-26C4A167-6D5D-4EF6-8741-4DA5FE70AA97Q28075293-1ABCD2EB-30E7-4782-9780-2F7BC3D5698EQ28082919-564ADCC5-6485-47FE-86F0-2CDF75D6A9F3Q28084785-5F6E072B-291F-4C54-A943-766047E8FFE0Q28085711-444CE902-1B64-4885-BABE-5EB7C175AB5FQ28487656-E8A078E3-1F4B-4BDC-AD0A-927178CC881BQ28533633-B6912A03-B528-404D-853A-461FF91E0F0EQ30355939-94F1BB70-5A5F-4318-BB21-B09035D4B7D7Q30424344-C9C2B069-A510-437A-983A-7A2621722992Q33326148-813D0AD7-4111-4308-9B58-470EA0B2ED59Q33350085-06EDAEAF-7F62-402D-83EA-55D45EE59289Q33371000-A24F6532-A34A-4743-8572-100B01F3E3D1Q33373308-CCFB8D46-BE5D-483A-B230-A1EC3FE1E845Q33378968-EFB9F8E2-99E9-41C4-B0E9-369DA22BF0C2Q33380084-5127CFA2-89C2-444D-B5B3-EB5A20070007
P2860
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@ast
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@en
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@nl
type
label
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@ast
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@en
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@nl
prefLabel
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@ast
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@en
Gemcitabine in combination wit ...... OR and GISCAD phase III trial.
@nl
P2093
P50
P356
P1476
Gemcitabine in combination wit ...... COR and GISCAD phase III trial
@en
P2093
A Zaniboni
A de Gramont
P304
P356
10.1200/JCO.2005.06.023
P407
P577
2005-05-01T00:00:00Z